Global perceptions of the current and future impacts of COVID-19 on hereditary angioedema management
- PMID: 34983717
- PMCID: PMC8749253
- DOI: 10.2500/aap.2022.43.210099
Global perceptions of the current and future impacts of COVID-19 on hereditary angioedema management
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has greatly affected health-care provision across the globe. Management of chronic ailments has become challenging because of the strained health-care resources and social distancing measures that prevent on-site clinical visits and treatments. Hereditary angioedema (HAE) is a debilitating, chronic disease characterized by unpredictable swelling attacks in various parts of the body. Controlling HAE symptoms often requires long-term prophylactic medication use and regular medical care; however, limited scientific information has been published about HAE medical care during the COVID-19 pandemic. Objective: To gather patient and health-care professional (HCP) perspectives on the global impact that COVID-19 has had, and the future impact it will have on HAE medical care and to identify differences in perceptions across economic and geographic boundaries. Methods: We conducted two independent but similar online global surveys to capture patient and HCP perspectives on the impact that COVID-19 has had, and the future impact it will have on HAE medical care. Results: Both patients and HCPs globally reported that the pandemic has limited the availability of HAE medical care, and they expect the restrictions to continue far beyond the pandemic. In addition, the results of our study suggested that telehealth use has increased across the globe but has been more successfully implemented in high-income countries. Conclusion: Patients and HCPs expect that HAE-related care will be negatively impacted by the pandemic for many years. Disparities in medical care and technologic infrastructure may exacerbate these challenges in non-high-income countries. Supportive tools and global infrastructure should be established to provide aid to non-high-income countries throughout the pandemic and several years after.
Conflict of interest statement
T. Craig has received research funding from BioCryst, CSL Behring, Takeda/Shire, and Ionis; speaker fees from CSL Behring, BioCryst, Sanofi, and Takeda/Shire; and consulting fees from BioCryst, CSL Behring, Grifols, Takeda, and Pharming. H. Longhurst has received grants, was a consultant and speaker for Adverum, BioCryst, CSL Behring, Intellia, Ionis, KalVista, Pfizer, Pharming, and Takeda/Shire. N. Bara has received speaker/advisor fees from Takeda/Shire, Pharming, and GlaxoSmithKline. The remaining authors have no conflicts of interest to declare pertaining to this article
Figures
References
-
- World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available online at https://www.who.int/director-general/speeches/detail/who-director-genera...; accessed April 21, 2021.
-
- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available online at https://covid19.who.int/; accessed April 21, 2021.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
